ELUT press release
Key Highlights
- ➤NXT-41x GLP rabbit study eradicated 8-log MRSA and 6-log E. coli challenges
- ➤NXT-41x FDA submission planned for fourth quarter of 2026
- ➤Elutia added $26 million without an equity offering, funding anticipated 2028 commercialization
- ➤Cardiovascular sales rose 20% to $1.1 million in third quarter 2026
- ➤Net loss narrowed to $1.3 million from $3.9 million year over year
Expert Statements
Randy Mills, Chief Executive Officer of Elutia
“Patients and surgeons have been ignored for too long”
Randy Mills, Chief Executive Officer of Elutia
“Walking the ASPS annual meeting in Houston, I was astonished by the disconnect between what surgeons are worried about and what industry is offering.”
Randy Mills, Chief Executive Officer of Elutia
“Infection came up in all 11 breast research sessions, with rates reported as high as 23%.”
Randy Mills, Chief Executive Officer of Elutia
“Those numbers tell the story of an unacceptable problem and the definition of a serious unmet medical need.”
Randy Mills, Chief Executive Officer of Elutia
“We are out to solve it, and will take the next step this quarter with the NXT-41x FDA submission.”
Randy Mills, Chief Executive Officer of Elutia
“After adding $26 million without an equity offering, we believe we have the technology, the team, and the capital to advance NXT-41x toward anticipated clearance in the first half of 2027 and through the first full year of commercial launch in 2028.”
Randy Mills, Chief Executive Officer of Elutia
“In doing so, we will help patients thrive without compromise”
* Infection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection rates reported as high as 23%.
* NXT-41x In Vivo Study Supports Planned Q4 2026 FDA Submission: The GLP rabbit antibacterial study achieved its prespecified performance endpoints, with no viable bacteria recovered after either the 8-log MRSA challenges or the 6-log E. coli challenges, demonstrating robust eradication of relevant pathogens.
Get started
Create a free account to read the full story.